欧林生物：签署AC结合疫苗市场推广服务补充协议

Core Viewpoint - The company has signed a supplementary agreement with Keyuan Trading to optimize the promotion period for the AC combined vaccine from 2024 to 2029, with a total promotion task of 4 million doses [1] Group 1 - The initial agreement was signed in December 2023, with a promotion task of 4 million doses from 2024 to 2026 [1] - The new agreement extends the collaboration period to January 1, 2024, through December 31, 2029, while keeping other core terms unchanged [1] - The expected vaccine sales for 2024 are projected at 252,000 doses, but there are uncertainties regarding the completion of the promotion task and the fulfillment of the agreement [1]